Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: A meta-analytical approach

International Journal of Clinical Practice

Volumn 63, Issue 5, 2009, Pages 766-775

  Nixon, R M ^a   Muller E ^b   Lowy, A ^a   Falvey, H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Analytica International ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 64149092737     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02028.x     Document Type: Article

References (44)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005 365 : 217 23.
2. Whitworth JA. World Health Organization (WHO)-International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 21 : 1983 92.
3. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001 345 : 479 86.
4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345 : 1667 75.
5. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349 : 1893 906.
6. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363 : 2022 31.
7. Halpern M, Falvey H. The Impact of Valsartan vs. Losartan Therapy on 24-Hour Ambulatory BP and Long-Term Cardiovascular Outcomes. Poster No. 1308, ESH - 17th European Meeting on Hypertension, Milan, 2007.
8. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003 9 : 424 9.
9. Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 2004 26 : 460 72.
10. Jan SA, Patel JV, Welz J, Ishak P. A retrospective database analysis of prescribing patterns for specific angiotensin receptor blockers. Drug Benefits Trends 2005 17 : 23 9.
11. Pool JL, Guthrie RM, Littlejohn TW et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998 11 (4 Pt 1 462 70.
12. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007 9 : 187 95.
13. Moher D, Cook DJ, Jadad AR et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 1999 3 : i-98.
14. Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000 13 (4 Pt 1 418 26.
15. Baguet JP, Robitail S, Boyer L, Debensason D, Auquier P. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005 5 : 131 40.
16. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig 2007 27 : 735 53.
17. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002 21 : 1559 73.
18. Reif M, White WB, Fagan TC et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998 82 : 961 5.
19. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998 7 : 53 9.
20. Zuschke CA, Keys I, Munger MA et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators. Clin Ther 1999 21 : 464 74.
21. Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich, Conn) 2001 3 : 16 21.
22. Kloner RA, Weinberger M, Pool JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001 15 : 87.
23. Vidt DG, White WB, Ridley E et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001 15 : 475 80.
24. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999 12 (8 Pt 1 797 805.
25. Fogari R, Ambrosoli S, Corradi L et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group. J Hypertens 1997 15 (12 Pt 1 1511 8.
26. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 111 : 1012 8.
27. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan-Losartan Study Investigators. Am J Hypertens 1998 11 (4 Pt 1 445 53.
28. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich, Conn) 2001 3 : 283 91, 318.
29. Ali G, Kamili MMA, Kumar M et al. Efficacy & tolerability of losartan compared with amlodipine in the treatment of essential hypertension. JK Pract 2001 8 : 140 2.
30. Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997 6 : 35 43.
31. Mallion JM, Siche JP, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. The Telmisartan Blood Pressure Monitoring Group [see comments]. J Hum Hypertens 1999 13 : 657 64.
32. Monterroso VH, Chavez VR, Carbajal ET et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Adv Ther 2000 17 : 117 31.
33. Chung O, Hinder M, Sharma AM et al. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol 2000 14 : 31 41.
34. Hedner T, Oparil S, Rasmussen K et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999 12 (4 Pt 1 414 7.
35. White WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J 2002 144 : 657 65.
36. Chen JH, Cheng JJ, Chen CY et al. Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients. Int J Clin Pract Suppl 2004 145 : 29 34.
37. McGill JB. Angiotensin II receptor antagonist plus a thiazide diuretic is more efficacious for treating hypertension than either drug alone. Blood Press Monit 2001 6 (Suppl. 1 S3 13.
38. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998 15 : 229 40.
39. Nalbantgil I, Nalbantgil S, Ozerkan F et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004 145 : 50 4.
40. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 29 : 563 80.
41. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan-hydrochlorothiazide combination therapy at doses up to 320-25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007 29 : 61 73.
42. Mallion JM, Carretta R, Trenkwalder P et al. Valsartan- hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003 1 : 36 43.
43. Parati G, Mengden T, Brudi P, Kandra A, Di Giovanni R, Asmar R. Efficacy and safety of valsartan 160 mg and 320 mg od as monotherapy in mild to moderate essential hypertension. J Hypertens 2006 24 (Suppl. 4 S20.
44. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007 370 : 221 9.